The US Food and Drug Administration (FDA) has approved the United States' first biosimilar drug to treat cancer.

Avastin®, a cancer drug, has been shown to increase patient death from adverse events when used in conjunction with chemotherapy or biological therapy, according to new analysis of previous studies.